LoginSubscribe Now
International In-house Counsel Journal Logo
International In-house Counsel Journal Logo
  • Home
  • Business Sectors
  • Areas of Law
  • Editorial Board
  • Write a Paper
  • Subscribe
  • Books
  • Reports
  • Back Issues
  • Terms and Conditions
  • Cookie Policy
  • Privacy Policy
  • PLS LogoCopyright & permissions
© 2026 International In-house Counsel Journal Ltd. | ISSN 1754-0607 | Picture Credits: Freepix, Unsplash and by permission of the authors

Library search

Conducting Effective Global Anti–Money Laundering Investigations in a Complex Regulatory Environment
Money LaunderingPharmaceutical
Global anti–money laundering (AML) investigations present complex operational and regulatory challenges driven by cross-border transactions, fragmented data sources, varying legal regimes, data protection and privacy requirements, and cultural barriers to...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Kwanza Burney
Kwanza Burney
Compliance & Risk Professional | M.S.L. Candidate (Fordham Law), Fordham University School of Law, USA
“Crisis-Capable Compliance: The CCO at the Crossroads of AI, Ethics, and Leadership”
CompliancePharmaceutical
The role of the Chief Compliance Officer is undergoing a fundamental transformation in the era of artificial intelligence. No longer confined to oversight and enforcement, the CCO is emerging as...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Dolores Guzman
Dolores Guzman
Legal & Compliance Director, Apex America, UK
Implementing Effective Compliance Programs in Jurisdictions Where the Rule of Law is Weak
CompliancePharmaceutical
Multinational organizations increasingly operate in jurisdictions where the rule of law is weak, inconsistently enforced, or subject to political and economic influence. For pharmaceutical and biotechnology companies, these environments present...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Valentina Lacerca-Allen
Valentina Lacerca-Allen
Title Marketing/ Communication Specialist, Ethiprax LLC., USA
March-In Rights at a Crossroad: What Biopharma Needs To Know Under Trump Administration
Intellectual PropertyPharmaceutical
Few pieces of legislation have shaped the modern innovation landscape as profoundly as the Bayh-Dole Act of 1980. By allowing universities, small businesses, and non-profit organizations to retain ownership...Read more
Portrait image of Joanna Brougher
Joanna Brougher
Owner & Principal, BioPharma Law Group PLLC, USA
Portrait image of Bhavya Bhardwaj
Bhavya Bhardwaj
Student, University of Pennsylvania, USA
Patent Strategies for Attenuated Pathogen Vaccines
Intellectual PropertyPharmaceutical
Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more
Portrait image of David Dolberg
David Dolberg
Senior Director of Intellectual Property, Sanaria Inc., USA
Ways to Avoid Having your Patents Cellected*
Intellectual PropertyPharmaceutical
The Court of Appeals for the Federal Circuit caused frustrations when it decided to affirm the U.S. Patent Office’s findings that claims in four patents were unpatentable because they are...Read more
Portrait image of Tom Irving
Tom Irving
Partner, Marbury Law Group, USA
Portrait image of Xiaoguang Michelle Gao
Xiaoguang Michelle Gao
Associate VP - Assistant General Patent Counsel, Eli Lilly and Company, USA
Portrait image of Michelle E. O'Brien
Michelle E. O'Brien
Partner, Marbury Law Group, USA
Supported Studies Quid Pro Quo
AdvertisingPharmaceutical
Many pharmaceutical companies (hereinafter Companies or Company) recognize the importance of supporting external studies and the role they play in fulfilling patients’ needs. High standard ethical research conducted by external...Read more
Portrait image of Ann Turi
Ann Turi
Senior Legal Counsel, Legal and Compliance R&D and Medical Legal Team, Gsk, USA
Section 112 Requirements for Life Sciences Patents
Intellectual PropertyPharmaceutical
35 U.S.C. §112(a) of the US Patent Act is one of the integral parts of the quid pro quo patent system that balances the benefit of disclosure of the invention...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
A Current Look at the State of Inequitable Conduct and Other Equitable Concerns
Intellectual PropertyPharmaceutical
Inequitable conduct is an “equitable defense to patent infringement that, if proved, bars enforcement of a patent. ” Therasense, Inc. v. Becton, Dickinson & Co. , 649 F. 3d 1276,...Read more
Portrait image of Tom Irving
Tom Irving
Partner, Marbury Law Group, USA
Portrait image of Xiaoguang Michelle Gao
Xiaoguang Michelle Gao
Associate VP - Assistant General Patent Counsel, Eli Lilly and Company, USA
Portrait image of Stacy Lewis
Stacy Lewis
Law Clerk, Finnegan, USA
Portrait image of Jordan Cowger
Jordan Cowger
Finnegan, USA
Portrait image of Melissa Santos
Melissa Santos
Finnegan, USA
Induced Infringement under US Patent Law
Intellectual PropertyPharmaceutical
Induced infringement finds its basis in 35 U.S.C. § 271(b) and holds a person, liable if he actively causes infringement, even if the actor himself is not the direct infringer....Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
Portrait image of Jatin Jalundhwala
Jatin Jalundhwala
Joint President Legal and Company Secretary, Adani Group, India
1234…6